Objectives: To determine whether ␤-adrenergic blockade inhibits choroidal neovascularization (CNV) in a mouse model of laser-induced CNV and to investigate the mechanism by which ␤-adrenoreceptor antagonism blunts CNV.
E
XUDATIVE AGE-RELATED macular degeneration (AMD) is one of the leading causes of blindness worldwide. 1 Exudative AMD develops when vascular tissue from the choriocapillaris invades through a break in the Bruch membrane into the subretinal pigment epithelium and/or subretinal space; this process is termed choroidal neovascularization (CNV). Leakage of blood, serous fluid, and lipid due to CNV causes central vision loss and ultimately leads to an irreversible fibrovascular scar. 1 Histopathological studies of CNV membranes have provided valuable insight into the pathogenesis of exudative AMD. Several studies identified choroidal endothelial cells (ChECs), retinal pigment epithelial (RPE) cells, fibroblasts, myofibroblasts, photoreceptors, glial cells, and macrophages within surgically excised CNV membranes. [2] [3] [4] [5] [6] Follow-up studies focusing on growth factor expression demonstrated interleukin 1␤, 7 tumor necrosis factor, 7 tissue factor, 8 monocyte chemotactic protein, 8 transforming growth factor ␤, 9, 10 acidic and basic fibroblast growth factors, 9 ,10 platelet-derived growth factor, 10 and vascular endothelial growth factor (VEGF) [6] [7] [8] [10] [11] [12] [13] within these CNV membranes. Expression of VEGF is localized to RPE, choroidal endothelium, fibroblasts, and macrophages. [6] [7] [8] [10] [11] [12] [13] Because VEGF is a secreted protein that stimulates vascular permeability and angiogenesis, 14, 15 we hypothesized that VEFG plays a central role in CNV.
Experimental models demonstrate a causative role for VEGF in CNV. In the laser-induced model, VEGF is upregulated in the RPE, choroidal endothelium, fibro-blasts, and macrophages. 16 In this same model, inhibition of VEGF signaling prevents CNV. 17 These studies demonstrate that VEGF is correlated with and necessary for CNV. Overexpression of VEGF in photoreceptors 18 and in the RPE 19 produces retinal and intrachoroidal neovascularization, respectively, that did not cross the Bruch membrane. However, adenoviral administration into the subretinal space, which damages the Bruch membrane and stimulates overexpression of VEGF in the RPE, causes CNV. 20 These studies demonstrate that a break in the Bruch membrane and elevated VEGF levels are sufficient for CNV. These studies led to the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) 21 and MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) 22 trials, which established anti-VEGF therapy as the criterion standard for treatment of exudative AMD.
Despite the significant breakthrough of anti-VEGF therapy, patients must undergo a large treatment burden, consisting of monthly intravitreal injections. Recently, it was discovered serendipitously that the ␤-adrenoreceptor blocker propranolol hydrochloride reduces periocular hemangiomas. 23, 24 The putative mechanism for this phenotype is the inhibitory action of ␤-adrenergic blockers on VEGF production in multiple nonocular cell types, [25] [26] [27] including endothelial cells. [28] [29] [30] [31] In the retina, propranolol or ␤ 2 -adrenoreceptor blockade inhibits neovascularization in the oxygen-induced retinopathy (OIR) model via reduced VEGF production. 32, 33 These studies suggest that ␤-adrenoreceptor blockade could be an alternative or adjunctive anti-VEGF treatment.
To test this hypothesis, we determined whether propranolol could suppress CNV in the laser-induced model. Because RPE and choroidal endothelium have been shown consistently to be sources of VEGF production in CNV, we established a model of norepinephrine bitartrate-induced VEGF production in primary mouse RPE cells and ChECs. We finally investigated which ␤-adrenoreceptor drives norepinephrine-stimulated VEGF expression. 34 Briefly, mice were anesthetized and treated with 3 focal laser burns in each eye. Propranolol hydrochloride was dissolved in citrate buffer and delivered daily via intraperitoneal injection at 20 mg/ kg. After 14 days, the mice were killed and CNV was measured on choroidal-scleral flat mounts using intercellular adhesion molecule 2 (BD BioSciences) immunofluorescence staining. Images were analyzed using public domain opensource software (http://rsbweb.nih.gov/ij/docs/concepts .html).
METHODS

REAGENTS
PREPARATION OF ANTIBODY-COATED MAGNETIC BEADS
Sheep anti-rat magnetic beads (Dynabeads; Invitrogen) were washed 3 times with serum-free basal medium (Dulbecco Modified Eagle Medium [DMEM]; Invitrogen) and then incubated with platelet endothelial cell adhesion molecule 1 antibody (MEC13.3; BD Pharmingen) overnight at 4ЊC (10-L beads in 1mL DMEM). After incubation, beads were washed 3 times with DMEM containing 10% fetal bovine serum (FBS), resuspended in the same medium, and stored at 4ЊC.
ISOLATION AND CULTURE OF ChECs AND RPE CELLS
Eyes from 1 litter (6 to 10 pups) of 4-week-old immortomice (mice from Charles River Laboratories were crossed to C57BL/6j for several generations) were enucleated, and all connective tissue and muscle were removed from the sclera. In cold DMEM, the anterior eye was removed, followed by the lens, vitreous, retina, and optic nerve, leaving only a tissue composed of RPE, choroid, and sclera. At this point, ChECs were isolated from the RPE-choroid-sclera complex identically to retinal endothelial cells as previously described, using anti-platelet endothelial cell adhesion molecule 1 antibody-coated magnetic beads. The ChECs were analyzed by means of fluorescent-activated cell sorting to document purity and grown identically to retinal endothelial cells. 35 For RPE cells, 2 sets of tweezers were used to remove the RPE sheet, which was then digested in 5 mL of type I collagenase (1 mg/mL in serum-free DMEM; Worthington Biochemical Company) for 45 minutes at 37ЊC. After digestion, DMEM with 10% FBS was added, and cells were centrifuged at 400g for 10 minutes. The cellular digest was filtered through a double layer of sterile 40-m nylon mesh (Fisher Scientific), centrifuged, and washed twice with DMEM containing 10% FBS. The RPE cells were plated into a single well of a 24-well plate precoated with a 2-g/mL solution of human fibronectin (BD Biosciences). To document purity, RPE cells were analyzed by means of fluorescent-activated cell sorting as previously described 35 using antibestrophin (MAB5466; Millipore) and anti-RPE65 (MAB5428; Millipore) antibodies. The RPE cells were grown in low-glucose DMEM containing 10% FBS, 2mM L-glutamine, 100 g/mL of streptomycin and 100 U/mL of penicillin per milliliter, and murine-recombinant interferon-␥ at 44 U/mL.
The ChECs and RPE cells were maintained at 33ЊC with 5% carbon dioxide in 1% gelatin-coated 60-mm dishes. Cells were not allowed to grow beyond 20 passages. Before the experiments, cells were serum starved overnight in serum-free medium. Serum-free medium was identical to the growth medium in the previous paragraphs except it lacked 10% FBS, and the ChEC medium also lacked endothelial cell growth supplement.
VEGF ANALYSIS
For messenger RNA (mRNA) analysis, cells were preincubated for 30 minutes and/or incubated for 2 hours in 24-well plates. Cells were then washed with phosphate-buffered saline (strength, 1ϫ), lysed in buffer (RLT plus; Qiagen), and frozen at Ϫ20ЊC. Messenger RNA was extracted using a commercially available kit (RNeasy Plus Mini Kit; Qiagen). The complementary DNA was synthesized using a reverse transcription-polymerase chain reaction kit (Sprint RT Complete-Double PrePrimed; Clontech). We measured VEGF mRNA levels using quantitative polymerase chain reaction analysis (Eppendorf) and normalized to the housekeeping gene for ribosomal protein L13A (RpL13A) by generating a delta threshold cycle value. Fold values were generated by normalizing to the vehicle control. Vehicle control samples were used to assay for baseline levels of VEGF and ␤-adrenoreceptors. The following primers were used: VEGFA-164 (forward, 5'-ATCTTCAAGCCGTCCTGTGTGC-3'; reverse, 5'-CAAGGCTCACAGTGATTTT-CTGG-3'),␤ 1 -adrenoreceptor(forward, 5'-GCCAGGAAGTGTTTCCCTTTGCTT-3'; reverse, 5'-AAGGTGAACCGTGCTCCACACATA-3'), ␤ 2 -adrenoreceptor (forward, 5'-GGTC-ATCACAGCCATTGCCAAGTT-3'; reverse, 5'-AAGTCCAGAACTCGCACCAGAAGT-3'), ␤ 3 -adrenoreceptor (forward, 5'-ACCGCTCAACAGGTTTGATGGCTA-3'; reverse, 5'-TGTTGCATCCATAGCCGTTGCTTG-3'), and RpL13A (forward, 5'-TCTCAAGGTTGTT-CGGCTGAA-3'; reverse, 5'-GC-CAGACGCCCCAGGTA-3').
For VEGF-secreted protein analysis, cells were incubated for 24 hours in 12-well plates. The VEGF levels were measured as previously described 35 and normalized to total protein from cell lysates using a protein assay kit (BCA; Pierce). Fold values were generated by normalizing to the vehicle control.
STATISTICAL ANALYSIS
For CNV and gene expression comparisons between cell lines, we performed the unpaired t test. For cell culture, each biological sample size was generated by an experiment on a unique passage day. Thus, we performed the paired (2-tailed) t test to compare 2 groups. For multiple comparisons, repeated-measures analysis of variance was performed using the Dunnett multiple comparison posttest against the vehicle control.
RESULTS
SUPRESSION OF CNV BY PROPRANOLOL
To determine whether ␤-adrenergic signaling plays a role in AMD, we tested propranolol in the in vivo laserinduced CNV model. Briefly, mice were anesthetized and treated with focal laser burns, which rupture the Bruch membrane and induce CNV. Mice were treated with propranolol or citrate vehicle control for 14 days and underwent assessment for CNV. We used intraperitoneal drug delivery because prior studies demonstrated positive results with this method. 32, 33 We found that propranolol reduced the average CNV area by 50% (Figure 1) .
STIMULATION OF VEGF PRODUCTION IN ChECs AND RPE CELLS BY ␤-ADRENORECEPTORS
We next sought to investigate the mechanism by which propranolol inhibits CNV. As discussed earlier, the choroidal endothelium and RPE have been consistently identified as key sources of VEGF production in histopathological studies of AMD. We thus began our in vitro analysis by assessing the levels of VEGF and ␤-adrenoreceptors in primary mouse ChECs and RPE cells. We found that ChECs and RPE cells express equal mRNA levels of Vegf and the ␤ 2 -adrenoreceptors (Figure 2) . However, ChECs displayed significantly less ␤ 1 -and ␤ 3 -adrenoreceptor mRNA compared with RPE cells (Figure 2B and D) .
Because primary ChECs and RPE cells express VEGF and all 3 ␤-adrenoreceptors, these cells are a good in vitro model to investigate the role of ␤-adrenergic signaling in VEGF production. To test this hypothesis, we incubated ChECs and RPE cells with norepinephrine, a naturally produced neurotransmitter and hormone that stimulates ␣-and ␤-adrenoreceptors. We found that norepinephrine increased Vegf mRNA production 4-fold in ChECs and RPE cells (Figure 3A and C) . In conditioned medium from these cells, norepinephrine incubation augmented VEGF secretion by 1.6-and 1.2-fold in RPE cells and ChECs, respectively ( Figure 3B and D) .
We next sought to inhibit the demonstrated effect with propranolol to replicate our CNV model in vitro and confirm that this effect is driven by ␤-adrenoreceptors. Propranolol completely inhibited norepinephrinestimulated Vegf mRNA production in ChECs and RPE cells (Figure 4) . Furthermore, propranolol prevented Vegf mRNA production only in the presence of norepinephrine and had no effect on baseline Vegf mRNA levels.
EFFECT OF ␤ 2 -ADRENORECEPTOR ON VEGF PRODUCTION
Because propranolol is a nonselective ␤-adrenoreceptor blocker, we next investigated which ␤-adrenoreceptor drives VEGF production. Before norepinephrine stimu- lation, we preincubated ChECs and RPE cells with selective ␤-adrenoreceptor antagonists CGP 20712 (␤ 1 -adrenoreceptor), ICI118 551 (␤ 2 -adrenoreceptor), and SR 59230A (␤ 3 -adrenoreceptor). We found that only the ␤ 2 -adrenoreceptor antagonist could prevent norepinephrinestimulated Vegf mRNA production ( Figure 5A and B). To confirm this result, we stimulated ChECs and RPE cells with selective ␤-adrenoreceptor agonists xamoterol (␤ 1 -adrenoreceptor), formoterol (␤ 2 -adrenoreceptor), and BRL 37344 (␤ 3 -adrenoreceptor). Only the ␤ 2 -selective agonist formoterol significantly increased Vegf mRNA production ( Figure 5C and D) . Treatment with the ␤ 3 -adrenoreceptor agonist also trended toward a small positive effect on Vegf mRNA production ( Figure 5C and D) .
COMMENT
Herein we demonstrated that ␤-adrenoreceptor antagonism was effective to diminish CNV in the laserinduced mouse model. Furthermore, we showed that norepinephrine stimulates VEGF mRNA production and secretion via the ␤ 2 -adrenoreceptor in primary ChECs and RPE cells. These results suggest that ␤ 2 -adrenoreceptor blockers could be effective anti-VEGF therapeutics in CNV-driven diseases, such as exudative AMD, traumatic choroidal rupture, myopic CNV, and ocular histoplasmosis.
The use of ␤-adrenergic antagonism to suppress VEGF production and neovascularization has been shown previously in rodent models of retinopathy of prematurity. In the rat, topical timolol maleate (a ␤-adrenoreceptor antagonist with highest affinity for the ␤ 2 -adrenoreceptor 36 ) diminishes retinal neovascularization during OIR. 37 More recently, a group from the University of Pisa showed that propranolol 32 and a selective ␤ 2 -adrenoreceptor blocker 33 can attenuate retinal neovascularization during OIR in mice by decreasing VEGF production. However, another group failed to demonstrate that propranolol could prevent retinal neovascularization in OIR mice. 38 Although Ristori et al 32 hypothesized that the ␤ 3 -adrenoreceptor stimulated VEGF expression because the ␤ 3 -adrenoreceptor was upregulated in OIR mice, Martini et al 3 3 conclusively demonstrated that the ␤ 2 -adrenoreceptor modulates this effect via receptorspecific antagonism. However, Dal Monte et al 39 showed that long-term administration of isoproterenol (a ␤ 1 -and ␤ 2 -adrenoreceptor agonist) attenuates retinal neovascularization in OIR mice, a result that is counterintuitive compared with Martini et al. 33 Attenuation occurs by agonistinduced desensitization of the ␤ 2 -adrenoreceptor. Our results agree with the findings of Martini et al 33 and Dal Monte et al, 39 that the ␤ 2 -adrenoreceptor is key in regulating VEGF expression. However, we see a trend toward increased Vegf mRNA production with ␤ 3 -adrenoreceptor agonism ( Figure 5 ), similar to the hypothesis of Ristori et al. 32 The ␤ 3 -adrenoreceptor might play a minor biological role in VEGF production, or we might be seeing off-target effects because the pharmacological modulators of ␤ 2 -and ␤ 3 -adrenoreceptors have some overlap with each other. In summary, our data agree with prior reports, which demonstrate a role for ␤ 2 -adrenoreceptordriven VEGF expression in OIR mice, and we extend these results to the laser-induced CNV model. Several published reports examine models of reduced ocular adrenergic signaling, but the results are conflicting. Chronic loss of adrenergic signaling in rats via surgical sympathectomy 40 or propranolol treatment 41 increases choroidal and retinal vascularity. Contrary to our findings, these results suggest that ␤-adrenergic signaling is antiangiogenic. On the other hand, several reports agree with our findings, showing that ␤-adrenergic signaling is proangiogenic. First, ␤ 3 -adrenoreceptor agonism stimulates elongation, migration, and proliferation of human retinal cells 42 and ChECs. 43 In addition, surgical sympathectomy in rats decreases VEGF levels, 44 whereas isoproterenol treatment in human ChECs increases VEGF expression. 45 These studies demonstrate that ␤-adrenoreceptor signaling is proangiogenic and drives VEGF expression, in agreement with our results.
In addition, surgical sympathectomy in rats, 46 Dbhnull mice (which cannot synthesize norepinephrine), 47 and mice null for ␤ 1 -adrenoreceptors 48 display degenerate capillaries, pericyte loss, and increased basement membrane thickness, which are all hallmarks of nonproliferative diabetic retinopathy. In agreement, ␤ 1 -adrenergic agonism reduces human retinal endothelial cell apoptosis. 49, 50 These results suggest that loss of ␤ 1 -adrenergic signaling can mimic early diabetic retinopathy. Our results identify the ␤ 2 -adrenoreceptor as a driver of VEGF expression; specific therapeutic antagonism of the ␤ 2 -adrenoreceptor should avoid the deleterious effects of ␤ 1 -adrenergic blockade.
Despite the wealth of knowledge about VEGF and its expression, the specific driver of VEGF expression in exudative AMD remains unknown. In proliferative diabetic retinopathy and central retinal vessel occlusions, VEGF expression is driven by hypoxia. 51 However, the choroid provides more blood flow than is necessary, and the role of hypoxia in AMD is unclear. Alternative hypotheses for drivers of VEGF expression in AMD include oxidative stress, 52 insulinlike growth factor 1, 53 inflammatory cytokines, 7 transforming growth factor ␤, 54 age, 55 and contact with choroidal endothelium. 55 Our results suggest that adrenergic signaling could also contribute to VEGF expression in CNV.
A potential negative consequence of anti-VEGF therapy istheinhibitionofRPE-derivedVEGFfornormalvisualfunction. Complete loss of RPE-derived VEGF expression causes absence of choriocapillaris development and poor vision. 56 Loss of RPE-derived soluble VEGF leads to choriocapillaris atrophy, RPE and Bruch membrane abnormalities, and photoreceptor death. 57 Importantly, ␤-adrenergic antagonism does not suppress baseline VEGF expression in RPE cells (Figure 4 ), suggesting that therapeutic ␤ 2 -adrenergic blockade would not have these complications.
Our studies have several important limitations and considerations for clinical translation. First, the laser-induced CNV model more closely approximates posttraumatic CNV after choroidal rupture and postinflammatory CNV in the context of diseases such as histoplasmosis than it does exudative AMD. Second, our studies used systemic, intraperitoneal drug delivery. Prior studies show that systemic propranolol therapy affects retinal phenotypes, including the electroretinogram 58 and neovascularization, 32, 33 demonstrating that systemic propranolol penetrates to the posterior eye. In addition, pharmacokinetic studies find that highly lipophilic ␤-adrenoreceptor blockers, such as propranolol, are most highly concentrated in the RPE and choroid after intravitreal or subconjunctival injection. 59, 60 Therefore, local propranolol could be highly effective for CNV owing to its lipophilic nature. These possibilities are subjects of future investigations in our laboratory.
Finally, our studies used primary RPE cells isolated from mouse retina that were successfully proliferated and readily passaged in culture without a significant effect on expression of RPE cell markers, including bestrophin and RPE65. We recognize that primary RPE cells may lose some of their in vivo quiescent characteristics on proliferation and passage in culture; thus, we have limited the extent of these cells' passage in culture. We normally do not see any significant changes in expression of RPE cell-specific markers in these cells at least up to the 25th passage. These potential limitations could be further addressed using primary human fetal RPE cells.
In summary, we have identified ␤ 2 -adrenergic signaling as a potential driver of RPE and ChEC VEGF expression promoting CNV. Future studies will extend these results to human models and expand the mechanism beyond the ␤ 2 -adrenoreceptor.
